Lung Cancer Focused Next Generation Sequencing Panel


Sunquest Code:LNGFOCCoPath Code:LNGFOC
Epic Code:LAB8060Epic Name:Lung Cancer Focused NGS Panel
Synonyms:NGS; EGFR; ALK; ROS1; BRAF; ERBB2; KRAS; MET; NRAS; PIK3CA; RET
Methodology:Next generation sequencing
Test Includes:ALK, BRAF, EGFR, ERBB2, KRAS, NRAS, PIK3CA, RET. In addition, all samples will be tested for the fusion profile. The fusions analyzed are listed:
FUSION: ALK, ROS1, NTRK1, NTRK3, RET, MET (exon 14 skipping alterations)
Turnaround Time:Performed Mon-Fri; results are reported within 10-14 days.
Special Instructions:Fixed samples: Include block number for testing.
Associated Links:

Gene Specific CPT Codes for Genetic Sequencing



Collection Instructions

Specimen:Fixed tissue slides (preferred)
Optimal Volume:Fixed tissue: 5 unstained slides (10 microns thick) and 1 H&E slide (10 microns thick) fixed tissue.
Minimum\Peds Volume:Fixed tissue: 5 unstained slides (10 microns thick) and 1 H&E slide (10 microns thick) fixed tissue.
Container:Plastic leakproof container, sterile
Causes for Rejection:Tissue: decalcified tissue, fixatives other than formalin used. Samples containing less than 10% tumor will not be tested.


Processing and Shipping

Specimen Processing:Do not process. Store at room temperature.
Shipping Instructions:Ship at room temperature. Do not refrigerate or freeze.
Stability:Do not refrigerate or freeze.
Test Performed at or Referral Lab Molecular Diagnostics  (UMMC-East Bank)


Interpretive

Reference Range:See interpretive report.
Use:NGS: This panel is indicated in the evaluation of non-small cell lung carcinoma to identify actionable mutations that help guide targeted therapy. If the focused panel is negative, reflex to a larger expanded gene panel is available if clinically indicated. Please contact the Molecular Diagnostic Laboratory at 612-273-8445 for more information.

Fusion Panel: Fusion detection for ALK, RET, ROS1, NTRK1 AND NTRK3. Detection of MET exon 14 skipping.

Clinical Use: This assay detects gene fusions seen in lung cancer, infantile fibrosarcoma, and other solid tumors to identify actionable rearrangements that guide targeted therapy selection and/or inform diagnostic classification. Please note that this assay does not detect NTRK2 alterations.


Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 6694"